Richard Snyder, Ph.D.
Vice President, Science & Technology, Pharma Services
Alachua, Florida, USA
Key roles and responsibilities
- Lead the science & technology team’s company wide initiative developing multi-generational manufacturing and analytical platforms used for the GMP production of advanced therapeutics, including viral, cellular, and nucleic acid-based modalities.
Professional highlights
- Co-founder and Chief Scientific Officer of Brammer Bio, which was acquired by Thermo Fisher Scientific in 2019
- Formerly an associate professor of molecular genetics and microbiology as well as director of biotherapeutic programs at the University of Florida; Adjunct Faculty Member, Institut National de la Sante et de la Recherche Medicale (INSERM), France; and assistant professor of pediatrics at Harvard Medical School
- Experience in the advanced therapeutics industry spans over thirty-five years; previously employed by Cell Cenesys, Somatix, Merlin, and Avigen
- Engaged in the development of gene transfer vector and vaccine technology along with therapeutic applications
- Author of more than 70 scientific publications and also eight U.S. patents
- National and international committees, including Ad-hoc Member of the NIH Recombinant DNA Advisory Committee (RAC) 1999, 2000; Consultant, FDA Cellular, Tissue and Gene Therapies Advisory Committee, 2006-2009; ASGCT Viral Gene Transfer Vectors Scientific Committee 2007 – 2010; ASGCT Bio Industry Committee, 2017 – 2021; Scientific Advisory Board, Irish National Institute for Bioprocessing Research and Training (NIBRT) 2020-present; Steering Committee member and Manufacturing Subteam member, The Foundation for the National Institutes of Health Accelerating Medicines Partnership Bespoke Gene Therapy Consortium (BGTC) 2021-present
Education
- Post-doctoral fellow at Johns Hopkins University School of Medicine
- Doctor of Philosophy in microbiology from The State University of New York at Stony Brook
- Bachelor’s degree in biology from Washington University in St. Louis
Scientific expertise
- Virus biology
- Viral vector development
- cGMP advanced therapeutics manufacturing & analytical technologies
- Viral vector mediated gene transfer
- Development of novel viral vector-based human gene therapies